Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

1.44
+0.150011.63%
Post-market: 1.440.00000.00%19:30 EDT
Volume:570.61K
Turnover:812.10K
Market Cap:9.59M
PE:-0.30
High:1.49
Open:1.35
Low:1.34
Close:1.29
52wk High:12.80
52wk Low:0.6201
Shares:6.66M
Float Shares:5.84M
Volume Ratio:2.02
T/O Rate:9.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7656
EPS(LYR):-8.3501
ROE:-660.08%
ROA:-95.77%
PB:2.07
PE(LYR):-0.17

Loading ...

Company Profile

Company Name:
FibroBiologics
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
- -
Office Location:
455 East Medical Center Boulevard,Suite 300,Houston,Texas,United States
Zip Code:
77598
Fax:
- -
Introduction:
FibroBiologics, Inc. was originally formed as a limited liability company under Texas law on April 8, 2021, and subsequently converted to a Delaware corporation on December 14, 2021. FibroBiologics is an early-stage cell therapy company headquartered in Houston, Texas, developing innovative therapies utilizing fibroblasts for the treatment of chronic diseases. The company's primary focus is initiating and advancing preclinical studies and clinical-stage FDA trials related to fibroblast-based treatments for degenerative disc disease, multiple sclerosis, cancer, wound healing, and other conditions.

Directors

Name
Position
Pete O Heeron
Chairperson and Chief Executive Officer
Matthew Link
Independent Director
Richard Cilento
Independent Director
Stacy Coen
Independent Director
Victoria Nikla
Independent Director
Robert Hoffman
Director

Shareholders

Name
Position
Pete O Heeron
Chairperson and Chief Executive Officer
Jason D. Davis
Chief Financial Officer
Hamid Khoja
Chief Scientific Officer
Ruben A. Garcia
General Counsel